11 completed, 6 unknown, 4 recruiting, 3 terminated. 28 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 28 | Completed 11, Unknown 6, Recruiting 4, Terminated 3, Active not recruiting 2, Withdrawn 2 |
| Phase 2 | 2 | Terminated 2 |
Follow Mantle Cell Lymphoma: new trials by email Literature Review of Mantle Cell Lymphoma trials Research Report on Mantle Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma Rocbrutinib, Ibrutinib, Acalabrutinib - Mantle Cell Lymphoma | Phase 3 | Recruiting | Guangzhou Lupeng Pharmaceutical Company LTD. | 394 | 2026-02-05 | 2026-02-06 |
| A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) Sonrotoclax, Zanubrutinib, Placebo - Mantle Cell Lymphoma, B Cell Lymphoma | Phase 3 | Recruiting | BeOne Medicines | 300 | 2025-03-05 | 2026-10-29 |
| A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL Orelabrutinib, Bendamustine Injection, Rituximab - Mantle Cell Lymphoma | Phase 3 | Recruiting | InnoCare Pharma Inc. | 476 | 2024-05-29 | 2024-12-27 |
| Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma Zanubrutinib, Rituximab, Patient Observation - Mantle Cell Lymphoma | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 421 | 2023-10-20 | 2026-11-03 |
| A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma parsaclisib, rituximab, bendamustine - Mantle Cell Lymphoma | Phase 3 | Withdrawn | Incyte Corporation | 2022-03-11 | 2022-04-29 | |
| Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma BTK inhibitor+ Fludarabine-based chemotherapy + CAR-T-CD19 Cells, Fludarabine-based chemotherapy + CAR-T-CD19 Cells - Diffuse Large B Cell Lymphoma, Burkitt Lymphoma | Phase 3 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 24 | 2021-09-14 | 2023-07-25 |
| Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies - High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified | Phase 3 | Unknown | Shandong Provincial Hospital | 130 | 2021-04-15 | 2021-11-19 |
| Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX, R-CHOP; R-DA-EPOCH; R-HD MTX - High Grade B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | Phase 3 | Unknown | Shandong Provincial Hospital | 160 | 2021-03-01 | 2021-12-21 |
| Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspirate - Mantle Cell Lymphoma | Phase 3 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 689 | 2017-11-27 | 2026-09-14 |
| ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma R-CHOP/R-DHAP, Ibrutinib (Induction), ASCT conditioning - Mantle Cell Lymphoma | Phase 3 | Unknown | Prof. Dr. M. Dreyling (co-chairman) | 870 | 2016-07-01 | 2017-12-19 |
| Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma Ublituximab, Umbralisib, Bendamustine - Diffuse Large B-Cell Lymphoma, Follicular Lymphoma | Phase 2 / Phase 3 | Terminated | TG Therapeutics, Inc. | 710 | 2016-05-25 | 2022-07-21 |
| A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma acalabrutinib, ibrutinib, rituximab - Mantle Cell Lymphoma | Phase 3 | Withdrawn | Acerta Pharma BV | 2016-05-01 | 2016-05-13 | |
| R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL R-CHOP, R-CHOP / R-HAD, Rituximab - Mantle Cell Lymphoma | Phase 3 | Completed | The Lymphoma Academic Research Organisation | 623 | 2013-11-01 | 2025-03-05 |
| A Long-term Extension Study of PCI-32765 (Ibrutinib) Ibrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 539 | 2013-09-09 | 2026-11-03 |
| A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma Bendamustine, Rituximab, Ibrutinib - Mantle Cell Lymphoma | Phase 3 | Completed | Janssen Research & Development, LLC | 523 | 2013-05-16 | 2025-07-08 |
| Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy Ibrutinib, Temsirolimus - Mantle Cell Lymphoma | Phase 3 | Completed | Janssen Research & Development, LLC | 280 | 2012-12-10 | 2018-01-19 |
| Double Cord Versus Haploidentical (BMT CTN 1101) Haploidentical Bone Marrow Transplant, Double Umbilical Cord Blood Transplant - Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia | Phase 3 | Completed | Medical College of Wisconsin | 368 | 2012-06-01 | 2021-12-01 |
| Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 3 | Completed | Fred Hutchinson Cancer Center | 174 | 2010-11-01 | 2026-04-30 |
| Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients Lenalidomide - MANTLE CELL LYMPHOMA | Phase 3 | Unknown | Fondazione Italiana Linfomi - ETS | 300 | 2010-05-01 | 2018-02-09 |
| A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL). Lenalidomide, Placebo - Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma | Phase 3 | Terminated | Celgene | 9 | 2010-04-01 | 2019-11-19 |
Showing 20 of 28. Sign in to see all of them.
Lymphoma, Mantle-Cell (28) · Lymphoma, Large B-Cell, Diffuse (7) · Lymphoma, Non-Hodgkin (7) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Lymphoma, Follicular (4) · Hodgkin Disease (3) · Multiple Myeloma (3) · Waldenstrom Macroglobulinemia (3) · Burkitt Lymphoma (2) · Hematologic Neoplasms (2) · Leukemia, Myeloid, Acute (2) · Lymphoma, B-Cell (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Bronchiolitis Obliterans Syndrome (1) · Leukemia (1)
Hemic and Lymphatic Diseases (28) · Immune System Diseases (28) · Immunoproliferative Disorders (28) · Lymphatic Diseases (28) · Lymphoproliferative Disorders (28) · Neoplasms (28) · Neoplasms by Histologic Type (28) · Lymphoma (27) · Lymphoma, Non-Hodgkin (21) · Hematologic Diseases (7) · Leukemia, Lymphoid (7) · Lymphoma, B-Cell (7) · Disease Attributes (6) · Leukemia (6) · Pathologic Processes (6)
Rituximab (14) · Bendamustine Hydrochloride (7) · ibrutinib (6) · Lenalidomide (3) · Whole-Body Irradiation (3) · zanubrutinib (3) · Bortezomib (2) · Cyclophosphamide (2) · Cyclosporine (2) · Cyclosporins (2) · Doxorubicin (2) · Magnetic Resonance Spectroscopy (2) · Mycophenolic Acid (2) · Peripheral Blood Stem Cell Transplantation (2) · Prednisone (2)
Janssen Research & Development, LLC (3) · Fred Hutchinson Cancer Center (2) · Prof. Dr. M. Dreyling (co-chairman) (2) · Shandong Provincial Hospital (2) · Acerta Pharma BV (1) · Alliance for Clinical Trials in Oncology (1) · BeOne Medicines (1) · Celgene (1) · Cephalon (1) · ECOG-ACRIN Cancer Research Group (1) · Fondazione Italiana Linfomi - ETS (1) · French Innovative Leukemia Organisation (1) · Guangzhou Lupeng Pharmaceutical Company LTD. (1) · Incyte Corporation (1) · InnoCare Pharma Inc. (1)
United States (14) · Germany (12) · China (9) · France (8) · Poland (8) · Spain (8) · Italy (7) · Australia (6) · Brazil (6) · Canada (6) · Portugal (6) · United Kingdom (6) · Belgium (5) · Czechia (5) · Israel (5)
Brenda Sandmaier (2) · Xin Wang, PhD (2) · Johanna Cornelia Kluin-Nelemans, Prof. Dr. (1) · Martin Dreyling, MD (1) · Martin Dreyling, Prof. (1) · Martin Dreyling, Prof. Dr (1) · Martin Dreyling, Prof. Dr. (1) · Mary Horowitz, MD, MS (1) · Owen A O'Connor, MD, PhD (1) · Sandeep Inamdar, MBBS (1) · Sergio Cortelazzo, MD (1)
PMID 32499241, PMID 36485104, PMID 23834234, PMID 24591201, PMID 25738670, PMID 26673811, PMID 26875824, PMID 28183846, PMID 28583031, PMID 28751558, PMID 28953447, PMID 29472356, PMID 30348538, PMID 30811293, PMID 31248843, PMID 31537689, PMID 31633999, PMID 33288485, PMID 33357480, PMID 33475736, PMID 33683917, PMID 34273598, PMID 35008361, PMID 35657079, PMID 37088401, PMID 37120135, PMID 38669626, PMID 38678093, PMID 38705160, PMID 39808795, PMID 39846144, PMID 41123227, PMID 41350757, PMID 42134356
P30CA015704 (2), 2009 (1), P01CA018029 (1), P01CA078902 (1), U10CA180820 (1), U10HL069294 (1), U24CA076518 (1)